Project Details
Description
The primary objective of the study is to collect additional safety data including the incidence rate of seizure and other specific Adverse Events (AEs) of interest from participants taking Fampyra in routine clinical practice. The secondary objectives of this study are to characterize utilization patterns of Fampyra in routine clinical practice, to assess the effectiveness of risk minimization measures as described in the risk management plan for Fampyra, to assess the change over time in participant self-reported evaluation of the physical and psychological impact of Multiple Sclerosis (MS) while taking Fampyra and to assess the change over time in physician assessment of walking ability in participants taking Fampyra (MS participants only).
| Acronym | LIBERATE |
|---|---|
| Status | Finished |
| Effective start/end date | 16/04/12 → 8/02/19 |
Collaborative partners
- Biogen (lead)
- Abu Dhabi Health Services Company
Keywords
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
- Demyelinating Diseases
- Autoimmune Diseases
- Immune System Diseases
- Multiple Sclerosis
- Potassium Channel Blockers
- Membrane Transport Modulators
- Molecular Mechanisms of Pharmacological Action
- 4-Aminopyridine
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.